BeOne Medicines (ONC) Cost of Revenue (2017 - 2026)
BeOne Medicines (ONC) posted quarterly Cost of Revenue of $167.2 million for Q1 2026, up 1.34% year-over-year from $165.0 million in Q1 2025, and up 17.41% quarter-over-quarter from $142.4 million in Q4 2025.
BeOne Medicines (ONC) Cost of Revenue (2017 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Cost of Revenue for 10 consecutive years, with $167.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cost of Revenue rose 1.34% year-over-year to $167.2 million; the TTM figure through Mar 2026 stood at $670.8 million (up 5.77% YoY), while the FY2025 annual figure was $668.5 million, up 12.53% from the prior year.
- Cost of Revenue climbed to $167.2 million in Q1 2026 per ONC's latest filing, from $142.4 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $196.5 million in Q3 2025 and bottomed at $65.2 million in Q1 2022.
- Historically, Cost of Revenue has averaged $123.3 million across 5 years, with a median of $124.9 million in 2024.
- Annual changes were most pronounced in 2022 — Cost of Revenue soared 99.59% — and 2025, when it dropped 11.3%.
- BeOne Medicines' Cost of Revenue stood at $73.5 million in 2022, then surged by 43.95% to $105.8 million in 2023, then surged by 51.71% to $160.6 million in 2024, then declined by 11.3% to $142.4 million in 2025, then gained by 17.41% to $167.2 million in 2026.
- Business Quant data shows ONC's Cost of Revenue at $167.2 million in Q1 2026, $142.4 million in Q4 2025, and $196.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 284,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 174.53 Mn |
| Jun 30, 2026 | 174.53 Mn |
| Mar 31, 2026 | 167.22 Mn |
| Mar 31, 2026 | 167.22 Mn |
| Dec 31, 2025 | 142.42 Mn |
| Dec 31, 2025 | 142.42 Mn |
| Sep 30, 2025 | 196.51 Mn |
| Sep 30, 2025 | 196.51 Mn |
| Jun 30, 2025 | 164.61 Mn |
| Jun 30, 2025 | 164.61 Mn |
| Mar 31, 2025 | 165.00 Mn |
| Mar 31, 2025 | 165.00 Mn |
| Dec 31, 2024 | 160.56 Mn |
| Dec 31, 2024 | 160.56 Mn |
| Sep 30, 2024 | 170.46 Mn |
| Sep 30, 2024 | 170.46 Mn |
| Jun 30, 2024 | 138.13 Mn |
| Jun 30, 2024 | 138.13 Mn |
| Mar 31, 2024 | 124.94 Mn |
| Mar 31, 2024 | 124.94 Mn |